(Total Views: 642)
Posted On: 01/04/2025 3:42:31 PM
Post# of 156338
"Both the 80 mg and the 100 mg dose of Resmetirom were superior to placebo with respect to NASH resolution and improvement in Liver Fibrosis by at least ONE stage".
"Will compare Leronlimab with a GLP-1 agonist (Semaglutide) in addition to Confirming the Comparison with Resmetirom...aka (Rezdiffra)...FDA approved.
In September, Cytodyn launched (two) follow-up studies which will become Available in January 2025.
Last letter to shareholders Dec 17th/2024...I expect PR before end of Jan.
Madrigal closed @ $319.69 for 1/3/25...with the daily bump of $5.91.
Cytodyn closed @ $0.1189 " ".
I would take their daily bump as a SP...to start.
"Will compare Leronlimab with a GLP-1 agonist (Semaglutide) in addition to Confirming the Comparison with Resmetirom...aka (Rezdiffra)...FDA approved.
In September, Cytodyn launched (two) follow-up studies which will become Available in January 2025.
Last letter to shareholders Dec 17th/2024...I expect PR before end of Jan.
Madrigal closed @ $319.69 for 1/3/25...with the daily bump of $5.91.
Cytodyn closed @ $0.1189 " ".
I would take their daily bump as a SP...to start.
(12)
(0)
